AIwithCare: Revolutionizing Clinical Trial Enrollment with Generative AI
AIwithCare has introduced a groundbreaking software platform that utilizes generative AI technology to efficiently screen patients for clinical trial eligibility. This innovative tool aims to expedite the process of identifying suitable candidates and enhancing overall enrollment in clinical research.
Innovative Tool for Clinical Trial Screening
Mass General Brigham has announced the development of AIwithCare’s AI tool, known as RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review). This cutting-edge tool was initially conceived by a team of researchers from Mass General Brigham’s Accelerator for Clinical Transformation, helping to redefine the landscape of patient eligibility determination.
Leveraging Generative AI for Enhanced Accuracy
RECTIFIER utilizes advanced generative AI to meticulously analyze a patient’s electronic health records (EHR), extracting key information related to diagnosis, health indicators, and medication history. Additionally, the tool is adept at evaluating unstructured data present in clinical notes and reports, which are often pivotal in establishing a patient’s eligibility for clinical trials. This automation significantly reduces the need for extensive manual reviews, ultimately saving time and reducing costs associated with patient enrollment.
The Importance of RECTIFIER in the Healthcare Landscape
With over 20 active implementations across various specialties, including cardiology, oncology, and neurology, the impact of RECTIFIER is evident. As Mass General Brigham extends the use of this AI tool throughout its health system, plans are in place to introduce it to other healthcare providers aiming to align patient populations with relevant clinical trials.
Enhancing Patient Identification and Reducing Burden
RECTIFIER is enhancing patient identification processes, effectively alleviating the burden of manual chart reviews in both clinical and population health contexts. For instance, pediatric gastroenterologists employ RECTIFIER to prioritize referred patients, yielding an impressive accuracy rate of 94.7% and 98% in identifying critical labs and symptoms hidden within clinical notes.
Mention of Clinical Success and Research Validation
A recent study published in NEJM AI highlights that RECTIFIER surpasses manual screening methods by more accurately identifying eligible patients for clinical trials at a lower cost. Additionally, a follow-up randomized trial, published in JAMA, revealed that the eligibility and registration rates achieved were nearly double those of traditional approaches. Importantly, the study found no significant differences in enrollment rates when controlling for external factors like race, gender, and ethnicity.
Commitment to Practical Innovation in Patient Care
Chris Coburn, Chief Innovation Officer at Mass General Brigham, states, “Advancing AI that can streamline patient matching with clinical trials reflects our commitment to practical innovation that strengthens patient care and expands access to promising therapies.” This strategic approach aims to dismantle barriers to care delivery while accelerating the pace of clinical research.
Summary and Future Outlook
With more than 1,400 active licenses and numerous new inventions disclosed over the past year, Mass General Brigham Innovation has played a pivotal role in facilitating AIwithCare’s emergence. As technologies like RECTIFIER continue to evolve, they hold the potential to significantly transform the clinical research landscape and enhance patient care across health systems worldwide.